HeartBeam & AccurKardia Partner to Expand Cardiac Monitoring Solutions

The partnership will integrate AccurKardia’s FDA-cleared ECG analysis software, AccurECG™, into HeartBeam’s cardiac devices.

HeartBeam, Inc. and AccurKardia have entered into a strategic collaboration to improve accessibility in cardiac monitoring technologies. 

The partnership will integrate AccurKardia’s FDA-cleared ECG analysis software, AccurECG™, into HeartBeam’s cardiac devices.

The collaboration combines HeartBeam’s credit card-sized, cable-free 3D ECG device with AccurKardia’s device-agnostic ECG interpretation platform. HeartBeam’s device, which captures heart signals in three non-coplanar directions and synthesizes them into a 12-lead ECG, is awaiting FDA clearance for its 12-lead ECG synthesis software.

Robert Eno, Chief Executive Officer of HeartBeam, stated, “This collaboration is a major step forward in delivering a more accessible and scalable solution for remote cardiac monitoring. AccurKardia shares our mission of improving cardiac outcomes through technological innovation, and together, we can accelerate the delivery of unprecedented cardiac insights to individuals and physicians outside of a medical facility.”

Focus on Clinical-Grade Data Accessibility

The integration of AccurKardia’s automated rhythm analysis is expected to support quicker arrhythmia assessments and facilitate faster diagnosis. Per HeartBeam, the collaboration will also expedite product development timelines while reducing costs.

In addition to advancing device functionality, the initiative aims to address existing gaps in cardiology services in the United States. By offering clinical-grade ECG insights outside traditional healthcare settings, the collaboration seeks to improve access for patients and healthcare providers facing specialist shortages.

Juan C. Jimenez, Co-Founder and Chief Executive Officer of AccurKardia, said, “By combining our strengths, we are creating a top-tier platform that revolutionizes the monitoring and detection of cardiac arrhythmia conditions. Our goal is to provide clinical-grade ECG insights directly to patients, addressing the growing shortage of access to cardiology specialists in the United States.”

Furthermore, HeartBeam is preparing to commercialize its 12-lead ECG synthesis technology, pending FDA clearance. 

The strategic collaboration with AccurKardia is expected to strengthen HeartBeam’s future offerings, which focus on early arrhythmia detection and patient-centered cardiac monitoring outside clinical facilities.